About the Project
Division: Cellular Medicine
Start Date: 20/09/21
Ovarian cancer, the most deadly gynaecological malignancy, frequently presents late, when chemotherapy is the most appropriate treatment (1). Response to first-line chemotherapy is variable, however, and a significant outcome predictor. Although many patients respond well, chemotherapy-induced “adaptive” drug resistance is common, while some 30% of patients are inherently drug resistant (2). Development of mechanism-based, biomarker-guided precision medicine approaches for chemotherapy prescribing in ovarian cancer would help clinicians to optimise drug selection and limit exposure to ineffective toxic drugs.
We have designed a longitudinal clinical study, the Dundee Ovarian Cancer Study (DOCS), creating matched series of serial blood samples and primary ascites-derived cell lines from drug-sensitive and drug-resistant patients. The DOCS study provides a unique opportunity to identify novel clinically relevant resistance mechanisms, and to develop quantitative biomarker assays.
To date (3-5), we have focussed on adaptive drug resistance mechanisms, using unbiased whole genome RNASeq and RPPA analysis to compare mRNA expression in drug-sensitive and drug-resistant patients. Bioinformatics analysis highlights marked inter-patient variation in gene expression, and has excitingly allowed us to identify common candidate drug resistance signatures consisent with expansion of a sub-population of inherently resistant cancer stem cells. The focus of this translational PhD project will focus on inherent drug resistance, correlating laboratory analysis (bioinformatics analysis of RNASeq and RPPA datasets, qRT-PCR analysis, Western blotting, immunohistochemical analysis, quantitative chemosensitivity, cell proliferation, invasion, migration and apoptosis assays following over-expression and siRNA-mediated transient gene knockdown) with detailed clinical histories from patients who responded well or were inherently resistant to first-line chemotherapy.
Applicants to complete the Application form and email to [Email Address Removed] along with a CV and 2 academic references by Monday 22nd March 2021.
First class honours degree, and/or a Masters degree in a relevant discipline. (Non-clinical applicants)
MBChB (clinical applicants)
English language requirements
IELTS minimum overall score of 6.5
Reading 5.5, Listening 5.5, Speaking 5.5 Writing 6.0
RCUK stipend rate for 4 years (non-clinical applicants)
University of Dundee Clinical Research Fellow scale for 3 years (clinical applicants)
2. Vaughan S, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 211(10):719-25.
3. Smith G, et al. (2012) Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. British Journal of Cancer 107(8): 1327-1336
4. Sawers L, et al. (2014) Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. British Journal of Cancer 111(6): 1150-1158.
5. Vaidyanathan A, et al. (2016) ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel and olaparib-resistant ovarian cancer cells. British Journal of Cancer 115: 431-441
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.